420 with CNW — New Mexico Court Makes Ruling on Insurance Coverage for Medical Cannabis Costs

A federal judge has ruled that health insurance providers in New Mexico aren’t legally required to pay for medical cannabis, even though some state laws suggest they should. This decision underscores the ongoing clash between state-level cannabis initiatives and overarching federal drug policies.

The lawsuit originated from a group of plaintiffs that included individuals enrolled in Medicaid or private insurance plans, along with a licensed cannabis dispensary. They claimed that marijuana used to treat mental and behavioral health conditions should be reimbursed under several New Mexico statutes, including the Behavioral Health Services Act and regulations on insurance practices. Their argument hinged on the idea that these laws collectively obligated insurers to cover medical cannabis.

But the court rejected those arguments, siding with major insurers—Western Sky Community Care Inc., Blue Cross & Blue Shield of New Mexico, and Presbyterian Health Plan Inc. The judge pointed to the state’s Benchmark Plan, which acts as a standard for insurance coverage. That plan doesn’t mention marijuana as a covered treatment and specifically excludes substances that lack FDA approval. Since marijuana has not been approved by the FDA, the court concluded that insurers have no legal duty to pay for it.

Federal law played a significant role in the ruling. The Medicaid Act allows coverage only for medications that have the FDA’s endorsement. Since marijuana is still considered a controlled substance at the federal level and hasn’t received formal medical approval, insurers would be violating federal law if they reimbursed patients for its use.

The plaintiffs referenced a state law that prohibits cost-sharing for certain behavioral health treatments, suggesting that patients shouldn’t bear the expense of medical marijuana. However, the court clarified that this law only applies to services that insurers are already required to cover—which, in this case, does not include cannabis.

There was mention during the case that federal cannabis laws could change in the future, potentially opening the door for insurance coverage. However, the judge noted that until such changes happen, federal restrictions remain in place. Offering coverage now could put insurers at legal risk.

Looking ahead, this might not be the final word. New Mexico legislators introduced a measure aimed at requiring insurance companies to cover medical cannabis in March. If that proposal becomes law, it could significantly shift how cannabis is handled within New Mexico’s health insurance system.

The broader industry, including firms like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) operating outside the U.S. hope that needed reforms can be made so that medical cannabis products can be covered by American insurance companies in order to ensure patients aren’t forced to incur high out-of-pocket costs while choosing these products to manage their symptoms.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — The Business and Legal Impact of Inconsistent Marijuana Testing Rules

Marijuana businesses operating legally across different states face a complicated reality when it comes to product testing. Without federal regulations, states have built their own rules around lab licensing, testing requirements, sampling methods, and even how to handle contaminated products.

This patchwork approach creates major headaches for companies, especially those working in multiple states, leading to inconsistent results, unexpected recalls, and financial risks.

In every legal state, cannabis must pass quality testing before reaching consumers. Labs need to be approved at the state level, but the way states license and accredit labs varies widely. Many states require labs to meet ISO standards for accuracy and reliability, while others have created alternative accreditation systems.

Since no nationwide testing methods exist, labs often develop their own procedures to meet local regulations, making it difficult to compare results across different regions.

One major problem is the inconsistency in what marijuana products must be tested for. Microbial contamination is a good example—some states demand zero tolerance for specific bacteria or mold, while others allow small amounts.

Pesticide testing rules also differ. Some states enforce strict bans on any pesticide residue, while others set thresholds, meaning trace amounts might still pass. Heavy metal testing is another area with differences. While most states test for mercury, arsenic, lead, and cadmium, some also require screening for additional metals like nickel and chromium.

THC potency testing is one of the few areas with broad agreement: almost all states require labs to measure THC levels for labeling. Still, states differ on how they calculate and define “Total THC” and whether they require testing for other cannabinoids like CBG or CBN.

Testing also changes depending on the product type. Marijuana flower usually faces the broadest testing requirements, while concentrates and edibles may have modified standards. For instance, concentrates often undergo solvent testing to ensure no harmful extraction chemicals are left behind. However, microbial testing may be relaxed for certain concentrate products since the extraction process can eliminate some microbes.

When it comes to topicals, edibles, and beverages, testing standards diverge even more. Some states believe that if the extract used in an edible passed all testing, the finished product doesn’t need to be retested. Others insist that the final product must be checked again.

Sampling procedures add another layer of inconsistency. Some states allow licensees to collect their own samples, while others require labs or neutral parties to do it to prevent tampering. Sampling sizes also vary: some states base it on a percentage of the batch, others on weight guidelines. These differences affect the reliability of test results and encourage practices like “lab shopping,” where companies look for labs that might deliver more favorable outcomes.

When a batch fails testing, the consequences depend heavily on local rules. Some states require immediate destruction, especially for serious contamination such as banned pesticides. Others allow remediation efforts, giving businesses a chance to fix and retest their products.

For marijuana operators trying to stay compliant, this fragmented system isn’t just a paperwork hassle—it can cause real financial damage. A failed batch, product recall, or lawsuit over testing can cost companies millions. Even when businesses do everything by the book, they might get caught up in recalls caused by lab errors or inconsistent standards.

For instance, Michigan regulators recalled all marijuana products tested over three months by a major laboratory in 2021. More than 400 dispensaries were impacted, and about $229 million worth of products were pulled from shelves.

As the industry evolves, businesses, regulators, and labs need a more unified system with shared testing standards and methods. Standardization would protect consumers, provide more stability for companies, and create a safer, more trustworthy industry overall.

For companies like Trulieve Cannabis Corp. (CBoe CA: TRUL) (OTCQX: TCNNF) that focus on making and selling medical marijuana products, uniform cannabis testing rules and practices are very important since lives can be impacted adversely if this crucial testing phase isn’t uniformly undertaken.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New York’s Social Equity Program Grapples with Predatory Investors

In 2022, a couple, Kim Stetz and her partner Marq Hayes submitted an application for a Conditional Adult-Use Recreational Dispensary (CAURD) license. Their goal was to open an adult-use marijuana store called Brown Budda in New York.

They were among over 900 applicants hoping to secure a social equity CAURD permit, a surprisingly low number given the state’s history of cannabis-related arrests.

Out of all the applicants, only 32 individuals were initially selected for provisional approval. Fast forward two and a half years and Brown Budda is fully licensed and had even launched delivery operations. However, the municipality they are operating in, Southampton, unexpectedly announced that a special-use license is required for delivery services.

According to Stetz, this demand is inaccurate. Despite disagreeing, they’ve decided to comply with the Town Council’s request and have paused their operations. Meanwhile, the business is sitting on a world-class location with a 15-year lease, yet facing opposition simply because the new Town Council isn’t thrilled with the choices their predecessors made.

On the financial front, the Brown Budda founders have faced many questionable offers. Wealthy investors frequently approach them, offering funding but demanding total ownership rather than fair loan terms or reasonable equity stakes.

Potential financiers are asking for half or more of the business once their conditional license transitions to a general license in 2028, or if they ever decide to sell. The couple has already spent over $50,000 on legal and consulting fees just to maintain full ownership. They have decided to hold out for a fair partnership or, ideally, find an affordable loan—an option that is slowly becoming available for marijuana enterprises.

Throughout this struggle, Stetz has noticed that investors appear far more focused on their personal profits than on supporting the individuals who have built the business from the ground up. This situation has made them question whether the social equity goals that New York intended with its cannabis rollout are being honored.

Thankfully, the Office of Cannabis Management (OCM) recently introduced the Trade Practices Bureau (TPB) to crack down on shady practices like predatory lending and fraudulent deals that could crush small cannabis businesses. Their mission is to protect the spirit of social equity and make sure big money doesn’t steamroll the entrepreneurs who were meant to benefit.

Real estate and funding challenges have put CAURD license holders in tough spots, often forcing them into unfair deals. Until things truly change, cannabis entrepreneurs like Brown Budda are left fielding shady offers, cannabis-style.

For those entering the cannabis space, Stetz encourages deep reflection on personal motives, advising newcomers to prioritize community and fairness over pure profit. Her advice is simple: listen to license holders and offer them genuinely fair deals based on their needs.

Established marijuana companies like Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) will be hoping that any loopholes allowing predatory investors to infiltrate the social equity program in New York State are plugged so that those who are earmarked as beneficiaries of that program do benefit from it.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — How Marijuana Descheduling or Rescheduling Would Impact the Industry

The potential shift in how cannabis is classified under federal law is stirring up discussions about the future of the cannabis industry and the possibility of opening up interstate trade. Although many U.S. states have already legalized cannabis for recreational, medical use, or both, it’s still illegal at the federal level, which limits the ability to create a unified national market.

According to Robin Goldstein, head of the Cannabis Economics Group at UC Davis, the direction of the sector is largely dependent on what the federal government does next. Whether cannabis will be reclassified or completely removed from the list of controlled substances remains unclear, leaving many cannabis business owners uncertain about what lies ahead.

Frank Colombo, a managing director at Viridian Capital Advisors, a firm focused on cannabis investments, expressed doubt that marijuana would be removed from the controlled substances list anytime soon. He said he’d be surprised if it happened in the next decade, let alone the next five years.

Industry experts have mixed views on how rescheduling—moving cannabis to a less restrictive category—versus descheduling—removing it entirely—would impact the sector. If cannabis gets moved to Schedule III, it would likely allow marijuana operators to access tax breaks that they currently can’t use due to Section 280E of the IRS code.

However, this wouldn’t necessarily change how marijuana is grown, sold, or transported across state lines. For those things to change, Congress would need to pass additional laws such as the SAFE Banking Act.

Legalizing interstate cannabis commerce would also bring up new questions about taxation. States would need to figure out how to handle products being imported from other regions. At the same time, any expansion into the pharmaceutical side of the market would likely require FDA approval, which is a costly and lengthy process with uncertain returns.

Goldstein points out that even if marijuana-based drugs were approved, most generic cannabis products already on the market couldn’t be patented, making it hard to compete with the profits seen in traditional pharmaceuticals.

If marijuana were completely descheduled, it would likely open the door to interstate commerce, but it could also trigger federal regulations and taxes. This might slow growth and increase costs for operators, giving illegal operators an edge due to their lower prices.

According to Colombo, states with lower cultivation costs, like Oklahoma, California, Washington, and Oregon, could benefit most if national trade becomes legal. On the flip side, companies that invested in indoor grow operations in states with poor outdoor growing conditions could be hurt. State governments, too, might see a drop in tax revenue if local cultivation shrinks.

Industry actors like Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) now have the task of preparing for both scenarios so that if rescheduling or descheduling happens, they are ready for it rather than scrambling to cope once the change has been made.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trucking Industry Says Outdated Federal Rules, Cannabis Testing Are Causing Trucker Shortages

A new report from two trucking industry companies highlights a growing problem in the field: a serious shortage of drivers, estimated at around 80,000 last year. One of the key reasons behind this, the report says, is the number of drivers testing positive for cannabis under the U.S. Department of Transportation’s (DOT) strict drug policies.

The paper— “Cannabis, Compliance and Driver Retention”—was produced by Fleetworthy and FreightWaves. It explains that most qualified drivers are being sidelined due to positive drug test results, often because they are unaware that federal rules don’t recognize cannabis legalization in individual states.

As more states move to legalize cannabis and its use becomes socially acceptable, the trucking industry faces new challenges in managing safety regulations. The report also discusses the rise of CBD and cannabis-based products and how current DOT rules haven’t adapted to reflect today’s legal landscape.

Under current DOT guidelines, truckers are tested for drugs before employment, randomly while on the job, after accidents, or when there is suspicion of impairment. If a driver fails a test, they are immediately taken off the road and must go through a process that includes evaluations, follow-up testing, and counseling. While some states, like Minnesota, offer protections for first-time offenses, the process often ends careers.

When a driver is removed, companies lose experienced personnel and must invest heavily in recruiting and training replacements, which increases costs and stress on the system.

The report suggests that reclassifying cannabis under federal law—from a Schedule I to a Schedule III substance—could help, especially by reducing stigma and acknowledging its medical use. However, such a change wouldn’t automatically affect DOT testing requirements, since driving is a high-risk job.

To help reduce the impact on drivers and improve retention, the report recommends increasing education around cannabis policies, offering better training, and updating testing methods. For instance, improved CBD labeling could help drivers avoid accidental THC exposure. More accurate drug tests, such as those using hair and saliva samples, could also be fairer than the standard urine tests, which can detect drug use long after the effects have worn off.

Though oral fluid testing was approved by DOT policy changes in 2023, the system isn’t fully operational yet due to delays in certifying testing labs.

Ultimately, the paper emphasizes the importance of keeping the conversation going among trucking companies, government bodies, and drivers to find practical solutions that balance safety and fairness.

Federal reforms to align state policies with federal law would allow more truckers to retain their jobs while benefiting from the cannabis products sold by licensed companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) and other domestic firms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — UK Government Report Says Drug Enforcement Triggers Increases in Violence

A government-commissioned report in the UK has found that efforts to crack down on drug activity through law enforcement are more likely to drive up violence rather than decrease it. While it’s unclear whether this will push the government to change course on drug policy, the findings are significant.

According to the report, existing evidence shows that drug-related policing does little to cut violence. In fact, many studies show the opposite—that such enforcement efforts often make things worse. The research also revisits earlier work on the topic, which concluded that stepping up police pressure on drug markets usually fails to curb violence and might increase it.

The report advises law enforcement agencies in the UK to weigh the potential for violence before launching operations focused on drugs, especially when these actions involve arresting key figures in drug networks or seizing large amounts of substances. These actions, while intended to disrupt illegal trade, often create instability and spark turf wars among criminal groups.

According to Transform Drug Policy Foundation senior analyst Steve Rolles, the unintended consequences of drug enforcement have been evident for years. He contends that the “war on drugs” has exacerbated the ongoing conflict between criminal organizations and law enforcement, making it possible for only the most vicious gangs to endure.

Rolles sees the report as an important moment, mainly because it comes from the Home Office. The office is responsible for issues such as policing and national security.

Many former law enforcement officers have also spoken out over the years about how drug enforcement can increase street violence. They point out that when established hierarchies in the drug trade are disrupted—through arrests or seizures—power vacuums form, sparking violent competition among rival groups.

Neil Woods, once an undercover cop, is now a leading advocate for changing drug laws. He chairs the Law Enforcement Action Partnership UK and argues that traditional drug policing doesn’t shrink the drug market. Instead, it often makes things more dangerous. He believes the findings of the report should influence government policy as public safety is at stake.

Woods also notes that cracking down on drug suppliers can increase overdose risks. A 2023 study published in the American Journal of Public Health showed that when a person’s dealer is arrested, they may turn to unfamiliar sources, increasing the chance of encountering contaminated or more potent drugs.

These findings are unlikely to surprise licensed marijuana companies like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) given that they have always believed that marijuana policy reform is a more sustainable way to reduce drug-related violence in different jurisdictions.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Largest-Ever Research Finds Medical Marijuana Could Help Combat Cancer

A recent study—the largest of its kind—has found strong scientific backing for the use of medical marijuana in managing cancer symptoms and possibly even affecting how the disease progresses. Published in Frontiers in Oncology, the research pulls together a vast amount of existing evidence to assess where science stands on the topic.

Ryan Castle, who leads research at the Whole Health Oncology Institute, spearheaded the analysis. According to him, the aim was to cut through years of conflicting studies and unclear messaging. A big challenge, Castle explained, is that marijuana is still categorized as a Schedule I drug at the federal level, which makes high-quality clinical research in the U.S. difficult to conduct.

The study was backed by Cancer Playbook, a group that works alongside the Whole Health Oncology Institute to gather and analyze patient feedback on treatments. Even though legal barriers limit formal trials on marijuana, there’s a huge volume of observational research and lab-based studies that look at how marijuana affects cancer—both in terms of symptom relief and its impact on cancer cells.

Castle’s team reviewed over 10,000 studies, far exceeding the scope of any previous analysis on this subject. To handle the massive dataset, they used artificial intelligence—specifically, a technique called sentiment analysis—to sort the findings. This allowed them to gauge how many studies supported marijuana, how many were neutral, and how many were negative. They looked at effects like reducing inflammation, improving appetite, and promoting cancer cell death, known as apoptosis.

Around 75% of the studies suggested that marijuana had a positive impact on cancer symptoms, and in many cases, also indicated it might help stop the disease from spreading.

Despite promising signs, there’s still debate. A 2024 JAMA study suggested a higher risk of neck and head cancers among those with marijuana-use disorder, but some critics, like UCSF oncologist Dr. Donald Abrams, argue that the study overlooked key risk factors like alcohol and tobacco use.

Abrams, who’s been treating cancer patients for over four decades, supports using marijuana to manage symptoms but is less convinced about its ability to treat cancer directly. Still, he acknowledges that lab studies have shown marijuana can impact tumors in animals and test tubes, though those results haven’t yet been mirrored in large-scale trials on humans.

Castle remains optimistic. He points to smaller human studies showing extended survival times or reduced tumor sizes in patients who received marijuana-based treatments alongside chemotherapy. However, he emphasizes that more robust human trials are essential.

Ultimately, Castle hopes the findings will help push U.S. regulators to reclassify marijuana, removing roadblocks to further clinical research.

The easing of existing barriers to research could allow products from licensed companies like SNDL Inc. (NASDAQ: SNDL) to be extensively analyzed for their therapeutic potential.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Most People in Canada Support Expanding the Marijuana Industry, Survey Finds

Most Canadians believe the government should do more to support the legal marijuana industry, according to a recent national poll. The survey, conducted by Abacus Data for Organigram Global, found that 64% of adults in Canada think the government should make it easier for the marijuana sector to expand. This view spans all regions and age groups.

Support was especially strong in Atlantic Canada, where 65% backed more government action. Similar levels of support were seen in British Columbia (61 percent), Ontario (62 percent), and the Prairies (64 percent). Even among citizens over 60—a group often more skeptical of cannabis—57% agreed that the industry deserves greater backing.

These results come at a time when Canada is heading into a federal election and facing economic uncertainty, particularly in light of strained trade relations with the United States. The marijuana sector, despite being relatively new, is becoming a significant player in the national economy. Last year, it added $7.4 billion to the nation’s GDP, outpacing sectors like forestry and brewing, which contributed $3.3 billion and $2.6 billion, respectively.

Beena Goldenberg, the CEO of Organigram, noted that Canadians want the government to help homegrown industries thrive, and marijuana is one of them. She emphasized that the incoming prime minister should focus on removing barriers that are holding the sector back.

Nearly 90% of respondents also said they believe Canada needs to explore new avenues for economic growth. A similar number agreed that the country should act quickly to capitalize on fresh opportunities in emerging industries.

Since cannabis was legalized in 2018, the sector has generated over $43 billion in GDP and now supports more than 80,000 jobs, according to figures cited from Deloitte.

The survey, conducted from April 3 to April 8, surveyed 1,915 adults in Canada. It has a margin of error of plus or minus 2.24%.

The analysis also outlined specific steps the government could take—such as simplifying taxes, easing interprovincial sales restrictions, and encouraging research and development. It suggested that targeted support could especially help regions hit hard by declines in traditional sectors.

While the rollout of marijuana legalization wasn’t perfect, most indicators point to a positive outcome. Previous surveys show Canadians are largely purchasing cannabis through legal channels now, and youth usage hasn’t spiked—countering fears raised by critics of legalization. A government report from December last year revealed that only 3% of consumers still turn to illegal sources.

If these sentiments are acted upon and the cannabis program is expanded, there could be room for entrepreneurs to start firms similar to Innovative Industrial Properties Inc. (NYSE: IIPR) that serve marijuana companies and create a lot more benefits through their operations.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Makers of THC-Infused Drinks Seek Adults to Participate in Observational Study

A group of cannabis beverage companies is launching a large-scale research project focused on how THC-infused drinks might affect alcohol use, mood, and overall well-being. The study is open to up to 2,000 adults who will receive complimentary marijuana beverages to use during the research period.

Other industry firms like Curaleaf Holdings Inc. (CBoe CA: CURA) (OTCQX: CURLF) will keep an eye on this study and…

420 with CNW — Delaware Lawmakers Consider Bills to Address Gaps in Marijuana Law

Two measures designed to speed up Delaware’s launch of its recreational cannabis market are currently under review in the state legislature. These legislative efforts come after delays have stalled the rollout of cannabis retail operations, despite business licenses being awarded last year.

Originally, the state had planned to open its recreational cannabis market this month. However, that timeline has been thrown off due to legal issues with the Marijuana Control Act—the law outlining the industry’s regulatory process. One of the main roadblocks is a delay in obtaining approval from the FBI to implement a fingerprint-based background check system, a requirement before the state can officially issue licenses.

Delaware’s regulators have already submitted two requests to the FBI, both of which were rejected. The problem lies in how the state’s law outlines applicant background checks—it needed to be adjusted to meet federal standards. Changes to address that were introduced earlier this month and passed the House. The goal is to get the legislation through both chambers quickly so the state can try again with the FBI.

The proposal is now before the Senate Executive Committee and will head to the full Senate for a vote. If approved and signed into law, the Marijuana Commissioner’s Office will be able to restart the process of conducting background checks and issuing conditional licenses to the 125 approved operators.

Even with licenses in hand, many businesses are struggling to find store locations. Strict zoning laws in the state’s three counties have created major obstacles. Around one-third of the state’s municipalities have completely banned cannabis retailers, and many others have made it very difficult to find compliant locations due to zoning buffers.

To address this, a second measure, SB 75, proposes loosening those zoning restrictions. The bill aims to standardize the minimum distance between cannabis stores and places like schools, treatment centers, and daycares to 500 feet. It also removes worship places from the list of protected areas.

Sussex County currently enforces a three-mile buffer, while New Castle sets a 1,000-foot limit between dispensaries and certain locations.

The measure also supports existing medical dispensaries—known as compassion centers—by allowing them to convert to recreational use and make necessary building changes. It also guarantees that indoor grow facilities can operate in industrial and agricultural zones and sets standard hours of operation for cannabis businesses.

While there was pushback from some GOP senators, especially over removing churches from the protected category and concerns about undermining local control, the bill passed the Senate with a 13-8 vote. It now moves to a House committee before heading to the floor for a final decision.

The broader marijuana industry, including entities like Green Thumb Industries Inc. (Cboe CA: GTII) (OTCQX: GTBIF) will be hoping that these pieces of legislation finally get the market launch back on track in Delaware.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com